The genetics of malignant melanoma: Lessons from mouse and man

Nature Reviews Cancer

Volumn 3, Issue 8, 2003, Pages 559-570

  Chin, Lynda ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; BASIC FIBROBLAST GROWTH FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; IMATINIB; MELANIN; MELANOCORTIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P14; PROTEIN P16; PROTEIN P19; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SCATTER FACTOR; UVOMORULIN; CORTICOTROPIN RECEPTOR; MELANOCORTIN RECEPTOR;

ANIMAL MODEL; AUTOSOMAL DOMINANT DISORDER; BANNAYAN ZONANA SYNDROME; CANCER SUSCEPTIBILITY; CDK4 GENE; CDKN2A GENE; CHROMOSOME 9P; CHRONIC MYELOID LEUKEMIA; COWDEN SYNDROME; ENZYME ACTIVATION; GENE; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOMICS; HAIR COLOR; HAMARTOMA; HETEROZYGOSITY LOSS; HUMAN; INK4A GENE; INK4B GENE; LHERMITTE DUCLOS DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; SOMATIC MUTATION; STROMA CELL; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION; ANIMAL; BIOLOGICAL MODEL; ENVIRONMENT; GENETIC PREDISPOSITION; GENETICS; MUTATION;

ANIMALS; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MICE; MODELS, BIOLOGICAL; MUTATION; PHENOTYPE; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; SIGNAL TRANSDUCTION;

EID: 0042887050     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1145     Document Type: Review

References (163)

1. Norris, W. A case of fungoid disease. Edinburgh Medicine and Surgery 16, 562-565 (1820).
2. Armstrong, B. K. & Kricker, A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B. 63, 8-18 (2001).
3. Gilchrest, B. A., Eller, M. S., Geller, A. C. & Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med. 340, 1341-1348 (1999).
4. Marrett, L. D., Nguyen, H. L. & Armstrong, B. K. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. Int. J. Cancer 92, 457-462 (2001).
5. Fountain, J. W., Bale, S. J., Housman, D. E. & Dracopoli, N. C. Genetics of melanoma. Cancer Surv. 9, 645-671 (1990).
6. Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 366, 753-756 (1994).
7. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994). References 6 and 7 identified CDKN2A as the tumour-suppressor gene deleted at the 9p21 cancer hot spot.
8. Hussussian, C. J. et al. Germline p16 mutations in familial melanoma. Nature Genet. 8, 15-21 (1994).
9. Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23-26 (1994). References 8 and 9 were the first to report germline mutation of CDKN2A in familial-melanoma kindred, linking cell-cycle dysregulation to hereditary cancer predisposition.
10. Kamb, A. Cell-cycle regulators and cancer. Trends Genet. 11, 136-140 (1995).
11. Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995). This paper reports the discovery of an alternative product, ARF, at the CDKN2A locus, which negatively regulates the cell cycle with a mechanism that is distinct from that of the cyclin-dependent kinase inhibitor INK4A
12. Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993).
13. Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 95, 8292-8297 (1998).
14. Pomerantz, J. et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998).
15. Stott, F. J. et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014 (1998).
16. Zhang, Y., Xiong, Y. & Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734 (1998). References 13 to 16 report the elucidation of the. biochemical link between ARF and p53 via its interaction with MDM2.
17. Glendening, J. M. et al. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 55, 5531-5535 (1995).
18. Aitken, J. et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J. Natl Cancer Inst. 91, 446-452 (1999).
19. Tsao, H. et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch. Dermatol. 136, 1118-1122 (2000).
20. Liu, L. et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nature Genet. 21, 128-132 (1999).
21. Kumar, R. et al. A single nucleotide polymorphism in the 3′ untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int. J. Cancer 95, 388-393 (2001).
22. Wolfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
23. Zuo, L. et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12, 97-99 (1996).
24. Soufir, N. et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7, 209-216 (1998).
25. Tsao, H., Benoit, E., Sober, A. J., Thiele, C. & Haluska, F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 58, 109-113 (1998). References 22 to 25 report the finding of R24 mutations in familial and sporadic human melanomas that render CDK4 insensitive to regulation by INK4A.
26. Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D. & Pavletich, N. P. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395, 237-243 (1998).
27. Goldstein, A. M., Struewing, J. P., Chidambaram, A., Fraser, M. C. & Tucker, M. A. Genotype-phenotype relationships in U. S. melanoma-prone families with CDKN2A and CDK4 mutations. J. Natl Cancer Inst. 92, 1006-1010 (2000).
28. Sotillo, R. et al. Invasive melanoma in Cdk4-targeted mice. Proc. Natl Acad. Sci. USA 98, 13312-13317 (2001). This study recapitulates the melanoma-prone effect of the Cdk4 R24C mutation in a mouse model.
29. Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378, F115-F177 (1998).
30. Piccinin, S. et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int. J. Cancer 74, 26-30 (1997).
31. Straume, O., Smeds, J., Kumar, R., Hemminki, K. & Akslen, L.A. Significant impact of promoter hypermethylation and the 540 C → T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol. 161, 229-237 (2002).
32. Kumar, R., Sauroja, I., Punnonen, K., Jansen, C. & Hemminki, K. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 23, 273-277 (1998).
33. Randerson-Moor, J. A. et al. A Germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10, 55-62. (2001).
34. Rizos, H. et al. A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF. Oncogene 20, 5543-5547 (2001). References 33 and 34 identified germline ARF mutations in human melanoma patients.
35. Duro, D., Bernard, O., Della Valle, V., Berger, R. & Larsen, C. J. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11, 21-29 (1995).
36. INK4a transcript. Cancer Res. 55, 2995-2997 (1995).
37. Stone, S. et al. Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 55, 2988-2994 (1995). References 35 to 37, as well as reference 11, describe the conserved genomic organization of the CDKN2A locus from opossum to man.
38. Swafford, D. S. et al. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol. Cell Biol. 17, 1366-1374 (1997).
39. Sherburn, T. E., Gale, J. M. & Ley, R. D. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica. DNA Cell Biol. 17, 975-981 (1998).
40. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
41. Chin, L. et al. Cooperativa effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822-2834 (1997). References 40 and 41 provide genetic proof in the mouse that the Cdkn2a locus functions as a bona fide tumour suppressor, specifically of melanoma, in vivo.
42. Yang, F. C., Merlino, G. & Chin, L. Genetic dissection of melanoma pathways in the mouse. Semin. Cancer Bol. 11, 261-268 (2001).
43. Bradl, M., Klein-Szanto, A., Porter, S. & Mintz, B. Malignant melanoma in transgenic mice. Proc. Natl Acad. Sci. USA 88, 164-168 (1991).
44. Bardeesy, N. et al. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell Biol. 21, 2144-2153 (2001).
45. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol. 19, 1-11 (1999).
46. Ross, D. A. & Wilson, G. D. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br. J. Surg. 85, 46-51 (1998).
47. Kraehn, G. M. et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br. J. Cancer 84, 72-79 (2001).
48. Schmitt, C. A, McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
49. Sharpless, N. E. et al. p16INK4a and p53 deficiency cooperate in tumorigenesis. Cancer Res. 62, 2761-2765 (2002).
50. Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A. & Berns, A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83-86 (2001).
51. Sharpless, N. E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91 (2001). References 50 and 51 show that Ink4a functions as a tumour suppressor in the mouse, as it does in humans.
52. Sharpless, N. E. et al. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene (in the press).
53. Valverde, P., Healy, E., Jackson, I., Rees, J. L. & Thody, A. J. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genet 11, 328-330 (1995).
54. Sturm, R. A. Skin colour and skin cancer: MC1R, the genetic link. Melanoma Res. 12, 405-416 (2002).
55. Box, N. F., Wyeth, J. R., O'Gorman, L. E., Martin, N. G. & Sturm, R. A. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum. Mol. Genet. 6, 1891-1897 (1997).
56. Smith, R. et al. Melanocortin 1 receptor variants in an Irish population. J. Invest. Dermatol. 111, 119-122 (1998).
57. Flanagan, N. et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum. Mol. Genet. 9, 2531-2537 (2000).
58. Palmer, J. S. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am. J. Hum. Genet. 66, 176 -186 (2000).
59. Bastiaens, M. et al. The melanocortin-1 -receptor gene is the major freckle gene. Hum. Mol. Genet. 10, 1701-1708 (2001).
60. Box, N. F. et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am. J. Hum. Genet. 69, 765-773 (2001).
61. Healy, E. et al. Melanocortin-1 -receptor gene and sun sensitivity in individuals without red hair. Lancet 355, 1072-1073 (2000).
62. Busca, R. & Ballotti, R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res. 13, 60-69 (2000).
63. Wildlund, H. R. & Fisher, D. E. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22, 3035-3041 (2003).
64. Harsanyi, Z. P., Post, P. W., Brinkmann, J. P., Chedekel, M. R. & Deibel, R. M. Mutagenicity of melanin from human red hair. Experientia 36, 291-292 (1980).
65. Scott, M. C. et al. Human melanocortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J. Cell Sci. 115, 2349-2355 (2002).
66. Kennedy, C. et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J. Invest. Dermatol. 117, 294-300 (2001).
67. van der Velden, P. A. et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am. J. Hum. Genet. 69, 774-779 (2001).
68. Hayward, N. K. Genetics of melanoma predisposition. Oncogene 22, 3053-3062 (2003).
69. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 (2002).
70. Yanase, H. et al. Possible involvement of ERK 1/2 in UVA-induced melanogenesis in cultured normal human epidermal melanocytes. Pigment Cell Res. 14, 103-109 (2001).
71. Busca, R. et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19, 2900-2910 (2000).
72. Lowes, V. L., lp, N. Y. & Wong, Y. H. Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals 11, 5-19 (2002).
73. Imokawa, G., Yada, Y. & Miyagishi, M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J. Biochem. 267, 24675-24680 (1992).
74. Gilchrest, B. A., Park, H. Y., Eller, M. S. & Yaar, M. Mechanisms of ultraviolet light-induced pigmentation. Photochem. Photobiol. 63, 1-10 (1996).
75. Tada, A. et al. Endothelin-1 is a paracrine growth factor that modulates melanogenesis of human melanocytes and participates in their responses to ultraviolet radiation. Cell Growth Differ. 9, 575-584 (1998).
76. Nesbit, M. et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 18, 6469-6476 (1999).
77. Dupin, E. & Le Douarin, N. M. Development of melanocyte precursors from the vertebrate neural crest. Oncogene 22, 3016-3023 (2003).
78. Jafari, M. et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 121, 23-30 (1995).
79. van Elsas, A. et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 149, 883-893 (1996).
80. Papp, T. et al. Mutational analysis of N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet. 36, 610-614 (1999).
81. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C. & van den Oord, J. J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 117, 1483-1489 (2001).
82. Albino, A. P. et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4, 1363-1374 (1989).
83. Papp, T. et al. Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J. Med. Genet. 40, E14 (2003).
84. Bastian, B. C. et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60, 1968-1973 (2000).
85. Powell, M. B. et al. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol. Carcinog. 12, 82-90 (1995).
86. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). This is a seminal study that not only identifies BRAF as a frequently mutated gene in human cancers, particularly in melanoma, but also serves as the proof-of-principle demonstration of the power of genome sequencing as a gene-discovery platform.
87. Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002).
88. Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20 (2003).
89. Cohen, C. et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728-3733 (2002).
90. Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991).
91. Vande Woude, G. F. et al. Met-HGF/SF: tumorigenesis invasion and metastasis. Ciba Found. Symp. 212, 119-130 (1997).
92. Li, G. et al. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20, 8125-8135 (2001).
93. Halaban, R. et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7, 2195-2206 (1992).
94. Natali, P. G. et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br. J. Cancer 68, 746-750 (1993).
95. Wiltshire, R. N. et al. Direct visualization of the clonal progression of primary cutaneous melanoma: application of tissue microdissection and comparative genomic hybridization. Cancer Res. 55, 3954-3957 (1995).
96. Bastian, B. C., LeBoit, P. E., Hamm, H., Brocker, E. B. & Pinkel, D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58, 2170-2175 (1998).
97. Rusciano, D., Lorenzoni, P. & Burger, M. M. Expression of constitutively activated hepatocyte growth factor/scatter factor receptor (c-met) in B16 melanoma cells selected for enhanced liver colonization. Oncogene 11, 1979-1987 (1995).
98. Otsuka, T. et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 58, 5157-5167 (1998).
99. Wu, H., Goel, V. & Haluska, F. G. PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122 (2003).
100. Stambolic, V. et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 (1998).
101. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997).
102. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356-362 (1997).
103. Li, D. M. & Sun, H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57, 2124-2129 (1997).
104. Guldberg, P. et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663 (1997).
105. Teng, D. H. et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57, 5221-5225 (1997).
106. Robertson, G. P. et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc. Natl Acad. Sci. USA 95, 9418-9423 (1998).
107. Hwang, P. H. et al. Suppression of tumorigenicity and metastasis in B16F10 cells by PTEN/MMAC1/TEP1 gene. Cancer Lett. 172, 83-91 (2001).
108. Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16, 64-67 (1997).
109. Marsh, D. J. et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genet. 16, 333-334(1997).
110. Nelen, M. R. et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6, 1383-1387 (1997).
111. Di Cristofano, A., Pesce, B., Cordon-Cordo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nature Genet. 19, 348-355 (1998).
112. Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563-1568 (1999).
113. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178 (1998).
114. You, M. J. et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice Proc. Natl Acad. Sci. USA 99, 1455-1460 (2002).
115. Schreiber-Agus, N. et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393, 483-487 (1998).
116. Holman, C. D. & Armstrong, B. K. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J. Natl Cancer Inst. 73, 75-82 (1984).
117. Autier, P. & Dore, J. F. Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer Int. J. Cancer 77, 533-537 (1998).
118. Whiteman, D. C., Whiteman, C. A. & Green, A. C. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12, 69-82 (2001).
119. Atillasoy, E. S. et al. UVB induces atypical melanocytic lesions and melanoma in human skin. Am. J. Pathol. 152, 1179-1186 (1998).
120. Berking, C. et al. Photocarcinogenesis in human adult skin grafts. Carcinogenesis 23, 181-187 (2002).
121. Jamal, S. & Schneider, R. J. UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells. J. Clin. Invest. 110, 443-452 (2002).
122. Donawho, C. K. & Kripke, M. L. Evidence that the local effect of ultraviolet radiation on the growth of murine melanomas is immunologically mediated. Cancer Res. 51, 4176-4181 (1991).
123. Pollock, P. M., Pearson, J. V. & Hayward, N. K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15, 77-88 (1996).
124. Peris, K. et al. UV fingerprint CDKN2a but no p14ARF mutations in sporadic melanomas. J. Invest. Dermatol. 112, 825-826 (1999).
125. Kyritsis, A. P. et al. Mutations of the p16 gene in gliomas. Oncogene 12, 63-67 (1996).
126. de Gruijl, F. R., van Kraneri, H. J. & Mullenders, L. H, UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J. Photochem. Photobiol. B. 63, 19-27 (2001).
127. Horiguchi, M. et al. Molecular nature of ultraviolet B light-induced deletions in the murine epidermis. Cancer Res. 61, 3913-3918 (2001).
128. Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415-428 (2002).
129. Noonan, F. P. et al. Neonatal sunburn and melanoma in mice. Nature 413, 271-272 (2001). This report provides the first experimental support for the long-held epidemiological observation that childhood sunburn confers a higher risk for melanoma development.
130. Noonan, F. P., Otsuka, T., Bang, S., Anver, M. R. & Merlino, G. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res. 60, 3738-3743 (2000).
131. Recio, J. A. et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res. 62, 6724-6730 (2002).
132. Kannan, K. et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Pro. Natl Acad. Sci. USA 100, 1221-1225 (2003). This paper reports genetic studies in the mouse that identify the Rb-pathway components (Ink4a and Cdk6) as key targets of the melanoma-promoting effect of UV light.
133. Bishop D. T. et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 94, 894-903 (2002).
134. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
135. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
136. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
137. Felsher, D. W. Cancer revoked: oncogenes as therapeutic targets. Nature Rev. Cancer 3, 375-380 (2003).
138. Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-472 (1999). This study is the first to show the use of an inducible onco-transgene model to study tumour maintenance.
139. Streit, M. & Detmar, M. Angiogenesis, lymphangiogenesis and melanoma metastasis. Oncogene 22, 3172-3179 (2003).
140. Hsu, M. Y., Wheelock, M. J., Johnson, K. R., & Herlyn, M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J. Investig. Dermatol. Symp. Proc. 1, 188-194 (1996).
141. Hsu, M. Y. et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156, 1515-1525 (2000).
142. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
143. DePinho, R. A. Transcriptional repression: The cancer-chromatin connection. Nature 391, 533-536 (1998).
144. Quelle, D. E., Cheng, M., Ashmun, R. A. & Sherr, C. J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad. Sci. USA 94, 669-673 (1997).
145. de Stanchina, E. et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998).
146. Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424-2433 (1998).
147. Radfar, A., Unrikrishnan, I., Lee, H. W., DePinho, R. A. & Rosenberg, N. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc. Natl Acad. Sci. USA 95, 13194-13199 (1998).
148. Chang, L, & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37-40 (2001).
149. Bennett, D. C. Genetics, development, and malignancy of melanocytes. Int. Rev. Cytol. 146, 191-260 (1993).
150. Jimbow, K., Quevedo W. C. Jr, Fitzpatrick, T. & Szabo, G. in Dermatology in General Medicine (eds. Fitzpatrick, T. B. et al.) 261-289 (McGraw-Hill, Inc, New York, 1993).
151. Hsu, M. Y., Meier, F. & Herlyn, M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70, 522-536 (2002).
152. Balch, C. M, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-3634 (2001).
153. Latres, E. et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19, 3496-3506 (2000).
154. Walker, G, J. et al. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22, 157-163 (1998).
155. Flores, J. F. et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers. in sporadic melanoma. Cancer Res. 58, 5023-5032 (1996).
156. Fujimoto, A., Morita, R., Hatta, N., Takehara, K. & Takata, M. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18, 2527-2532 (1999).
157. Sherr, C. J. & DePinho, R. A. Cellular senescence: mitotic clock or culture shock? Cell 102, 407-410 (2000).
158. Blackwell, T. K. & Weintraub, H. Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection. Science 250, 1104-1110 (1990).
159. Bertolotto, C. et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell Biol. 142, 827-835 (1998).
160. Price, E. R. et al. α-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J. Biol. Chem. 273, 33042-33047 (1998).
161. Brose, M. S. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000 (2002).
162. Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J. & Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62, 7001-7003 (2002).
163. Hamad, N. M. et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057 (2002).